A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Cannabidiol (Primary)
- Indications Rett syndrome
- Focus Registrational; Therapeutic Use
- Sponsors GW Research
- 03 Jun 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 May 2019 to 1 Jun 2019.
- 30 May 2019 Planned initiation date changed from 1 Apr 2019 to 1 May 2019.
- 30 May 2019 Status changed from not yet recruiting to recruiting.